You are here

  • Home
  • Archive
  • Volume 81, Issue 7
  • Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Citation Tools

Article menu
Systemic lupus erythematosus
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vital EM, Merrill JT, Morand EF, et al
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Annals of the Rheumatic Diseases 2022;81:951-961.